Enanta Pharma Reports Update on Collaboration Deal with AbbVie: Will Not Exercise Option for Co-Development, Co. Received $57M Related to Signing, $95M in Milestones

By: via Benzinga
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.